|
1. Biologie
|
|
|
|
|
Cancer’s Invasion Equation [The New Yorker]
|
|
|
|
|
|
Part
of the seduction of cancer genetics is that it purports to explain the
unity and the diversity of cancer in one swoop. For ecologists, by
contrast, everything is a relationship among a complex assemblage of
factors.
|
|
|
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
New Study Offers Support for Prostate Testing [NY Times]
|
|
|
|
|
|
Critics
of screening say the new analysis does not change much in the
calculation of risks versus benefits of screening. Only 3 percent of men
die of prostate cancer, so the benefit of screening, in the number of
prostate cancer deaths averted, is small in absolute terms.
|
|
|
|
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
FDA approves Mylotarg for treatment of acute myeloid leukemia [FDA]
|
|
|
|
|
|
The
U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab
ozogamicin) for the treatment of adults with newly diagnosed acute
myeloid leukemia whose tumors express the CD33 antigen (CD33-positive
AML). The FDA also approved Mylotarg for the treatment of patients aged 2
years and older with CD33-positive AML who have experienced a relapse
or who have not responded to initial treatment (refractory).
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.6 ESMO
|
|
|
|
5.6.14 ESMO - Ovaire
|
|
|
|
5.6.2 ESMO - Divers
|
|
|
|
5.6.6 ESMO - Sein
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|